We are one of the leading exporters of Resof to Russia.
Resof 400mg (Sofosbuvir) is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase - the key enzyme mediating HCV RNA replication. This triphosphate compound mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in chain termination.
Resof 400mg is available as a 400 mg tablet. The recommended dose of sofosbuvir is 400 mg taken orally once daily, with or without food. The 400 mg dose of sofosbuvir should be used, regardless of the patient's genotype and prior hepatitis C treatment experience. No dose adjustment is needed for mild-to-moderate renal impairment or with mild, moderate, or severe hepatic impairment.
Resof 400mg has been very well-tolerated in clinical trial. The most common adverse effects observed with sofosbuvir, when used in combination with ribavirin, have been fatigue and headache. Sofosbuvir is pregnancy category B.